Postmastektomi Radyoterapi Uygulamaları
Özet
Meme kanseri tedavisinde postmastektomi radyoterapisinin (PMRT) lokal tümör kontrolü ve genel sağkalım oranları üzerindeki kritik rolü, neoadjuvan kemoterapi sonrası klinik yaklaşım algoritmaları ve mastektomi sonrası meme rekonstrüksiyonu uygulanan olgulardaki güncel yönetim stratejileri büyük önem taşımaktadır. Tarihsel süreçte yürütülen Danimarka 82b/82c, British Columbia ve geniş ölçekli EBCTCG metaanalizleri gibi randomize faz III klinik araştırmalar, özellikle lokal ileri evre ve lenf nodu pozitifliği yüksek olan yüksek riskli hasta gruplarında PMRT uygulamasının lokorejyonel nüks riskini belirgin şekilde azalttığını, meme kanserine bağlı mortaliteyi düşürdüğünü ve uzun dönemli sağkalım avantajı sağladığını kesin verilerle ortaya koymuştur. Son yıllarda neoadjuvan kemoterapi kullanımının giderek artması, patolojik tam yanıt veren veya rezidüel invaziv hastalık barındıran vakalarda PMRT endikasyonlarının doğru optimize edilmesini ve hastaya özgü risk faktörlerinin multidisipliner bir yaklaşımla derinlemesine değerlendirilmesini zorunlu hale getirmiştir. Radyoterapi planlamasında göğüs duvarı ve supraklaviküler bölge gibi bölgesel lenfatiklerin hedef hacim olarak doğru tanımlanması kritik önem taşırken, eş zamanlı veya gecikmiş meme rekonstrüksiyonu uygulanan hastalarda implant veya otolog doku seçimi ile ışınlamanın zamanlaması; fibrozis, kapsüler kontraktür ve rekonstrüksiyon başarısızlığı gibi komplikasyon riskleri ve kozmetik sonuçlar açısından dikkatle koordine edilmelidir. Sonuç olarak PMRT, multidisipliner kurullarda şekillendirilen hastaya özgü yaklaşımlarla değer kazanmaktadır.
This comprehensive study meticulously examines the critical role of post-mastectomy radiotherapy (PMRT) in enhancing locoregional tumor control and overall survival rates within breast cancer management, while carefully analyzing clinical treatment algorithms following neoadjuvant chemotherapy and modern integration strategies for patients undergoing breast reconstruction. Historically significant large-scale randomized phase III clinical trials, including the Danish 82b/82c, British Columbia, and extensive EBCTCG meta-analyses, have conclusively demonstrated that incorporating PMRT substantially reduces locoregional recurrence risks and decreases breast cancer-specific mortality, particularly among high-risk, node-positive patient populations. With the steadily increasing utilization of neoadjuvant chemotherapy in contemporary oncology, optimizing PMRT indications for individuals achieving pathological complete response or presenting with residual invasive disease requires a highly sophisticated, multidisciplinary evaluation of patient-specific prognostic risk factors. While precise target volume delineation focuses inherently on the chest wall and regional lymphatics such as the supraclavicular and internal mammary chains, managing patients with breast reconstruction necessitates a careful balance regarding the choice between implant-based or autologous tissue and the exact timing of radiation therapy to mitigate substantial risks of fibrosis, capsular contracture, and reconstructive failure. Ultimately, the synthesized evidence highlights that rather than employing rigid standardized protocols, PMRT delivery must rely on individualized, multidisciplinary treatment planning tailored specifically to clinical characteristics.
Referanslar
Ragaz J, Olivotto IA, Spinelli JJ, Phillips N, et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst 2005;97(2):116-26.
Overgaard M, Jensen MB, Overgaard J et al. Postoperative radiotherapy in high risk postmenopausal breast cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 1999;353(9165):1641-8.
Overgaard M, Hansen PS, Overgaard J et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 1997;337(14):949-55.
Ragaz J, Olivotto IA, Spinelli JJ et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst 2005 ;97(2):116-26.
National comprehensive cancer network. NCCN guidelines, Breast Cancer 2022.
EBCTCG (Early Breast Cancer Trialists' Collaborative Group) Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet. 2014; 383(9935): 2127–35.
Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;366:2087-106.
Van de Steene J, Soete G, Storme G. Adjuvant radiotherapy for breast cancer significantly improves overall survival: the missing link. Radiother Oncol 2000;55:263-272.
Whelan TJ, Julian J, Wright J, Jadad AR, Levine ML. Does locoregional radiation therapy improve survival in breast cancer? A meta-analysis. J Clin Oncol 2000;18:1220-9.
Horton JK. Locally Advanced and Inflammatory Breast Cancer (Chapter 74). Gunderson LL, Tepper JE, editors. Clinical radiation oncology. 5th ed. Elsevier Saunders; 2021:1342-58.
Overgaard M, Nielsen HM, Tramm T, et al: Postmastectomy radiotherapy in high-risk breast cancer patients given adjuvant systemic therapy. A 30-year long-term report from the Danish Breast Cancer Cooperative Group DBCG 82bc trial. Radiotherapy and Oncology 2022; pre-proofs. https://doi.org/10.1016/j.radonc.2022.03.008
Mamounas EP, Anderson SJ, Dignam JJ, et al. Predictors of locoregional recurrence after neoadjuvant chemotherapy: Results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27. J Clin Oncol 2012;30:3960–6.
Huang EH, Tucker SL, Strom EA, et al. Radiation treatment improves locoregional control and cause-specific survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. J Clin Oncol 2004;22:4691–9.
Fowble BL, Einck JP, Kim DN, et al. Role of postmastectomy radiation after neoadjuvant chemotherapy in stage II-III breast cancer. Int J Radiat Oncol Biol Phys 2012; 83: 494–503.
Recht A, Gray R, Davidson N, et al. Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group. J Clin Oncol 1999; 17: 1689-1700.
Recht A. Evidence based indications for postmastectomy irradiation. Surg Clin North Am 2003; 83: 995-1013.
Strom EA, Woodward WA, Katz A, et al. Regional nodal failure patterns in breast cancer patients treated with mastectomy without radiotherapy. Int J Radiat Oncol Biol Phys 2005; 63: 1508-13.
Kunkler I. Radiotherapy of the regional lymph nodes: Shooting at the sheriff? Breast 2009; 18: 112-20.
Poortmans PM, Collette S, Kirkove C et al. Internal mammary and medial supraclavicular irradiation in breast cancer. N Engl J Med 2015; 373: 317-27.
Whelan TJ, Olivotto IA, Parulekar WR et al. Regional nodal irradiation in early stage breast cancer. N Engl J Med 2015; 373: 307-16.
http://www.rtog.org/corelab/contouringatlases/breastcanceratlas.aspx
Spear SL, Ducic I, Low M, et al. The effect of radiation on pedicled TRAM flap breast reconstruction: outcomes and implications. Plast Reconstr Surg 2005;115(1):84–95.
Hirsch EM, Seth AK, Dumanian GA, et al. Outcomes of immediate tissue expander breast reconstruction followed by reconstruction of choice in the setting of postmastectomy radiation therapy. Ann Plast Surg 2014;72(3):274–8.
Hirsch EM, Seth AK, Kim JY, et al. Analysis of risk factors for complications in expander/implant breast reconstruction by stage of reconstruction. Plast Reconstr Surg 2014;134(5):692–9.
Cordeiro P, Albornoz C, Mccormick B, et al. What is the optimum timing of post-mastectomy radiotherapy in two-stage prosthetic reconstruction: radiation to the tissue expander or permanent implant? Plast Reconstr Surg 2015;135:1509–1517.
Berbers J, van Baardwijk A, Houben R, et al. ‘Reconstruction: before or after postmastectomy radiotherapy?’ A systematic review of the literature. Eur J Cancer 2014;50(16):2752–62.
McCarthy CM, Mehrara BJ, Riedel E, et al. Predicting complications following expander/implant breast reconstruction: an outcomes analysis based on preoperative clinical risk. Plast Reconstr Surg 2008; 121:1886-92.
Lam TC, Hsieh F, Boyages J. The effects of postmastectomy adjuvant radiotherapy on immediate two-stage prosthetic breast reconstruction: a systematic review. Plast Reconstr Surg 2013;132:511-8.
Nahabedian MY, Dooley W, Singh N, et al. Contour abnormalities of the abdomen after breast reconstruction with abdominal flaps: the role of muscle preservation. Plast Reconstr Surg 2002;109(1):91–101.
Nahabedian MY, Manson PN. Contour abnormalities of the abdomen after transverse rectus abdominis muscle flap breast reconstruction: a multifactorial analysis. Plast Reconstr Surg 2002;109(1):81–7.
Jagsi R, Li Y, Morrow M, et al. Patient-reported quality of life and satisfaction with cosmetic outcomes after breast conservation and mastectomy with and without reconstruction: results of a survey of breast cancer survivors. Ann Surg 2015;261(6):1198–1206.
Kronowitz S, Robb G. Radiation therapy and breast reconstruction: a critical review of the literature. Plast Reconstr Surg 2009;124:395–408
Gurunluoglu R, Gurunluoglu A, Williams SA, et al. Current trends in breast reconstruction: survey of American Society of Plastic Surgeons 2010. Ann Plast Surg 2013;70(1):103–110.
